HDC to develop breast cancer prognostic test
This article was originally published in Clinica
Executive Summary
Pattern recognition technology specialist Health Discovery Corporation (HDC) is set to team up with Smart Personalized Medicine (SPM) to develop a breast cancer test. The two firms will create the test using HDC’s support vector machine (SVM) technology and will collaborate with the MD Anderson Cancer Center in Houston, Texas, for the product’s development. This partnership will see HDC (Savannah, Georgia) receive a 15% equity stake in SPM, as well as a $5m initial investment from its new partner. HDC will also receive a royalty for each test sold of up to 7.5% based on net proceeds. No further financial details were disclosed. According to HDC, its SVM technology allows scientists to access information in micro-array datasets that more advanced bioinformatics techniques miss. SPM was formed by former Integra Life Sciences chairman Dr Richard Caruso.